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with closure devices has been shown to reduce the risk of 
such complications. 14   
Another intravenous direct thrombin inhibitor is 
argatroban.15 The efficacy of argatroban has been 
demonstrated among patients with acute coronary 
syndromes and stroke. However, this drug is currently 
approved by the FDA only for the treatment of patients 
with heparin-induced thrombocytopenia. Although newer 
intravenous direct factor Xa inhibitors have been 
developed, they are still in the testing phase.16 
Fondaparinux is a long-acting indirect factor Xa 
inhibitor,17 but its use was associated with a high rate of 
catheter-related thromboses and thus has not been well 
received.  
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Athlete`s Heart or Athletic Heart Syndrome is a 
benign entity characterized by morphological changes of 
the heart muscle as a result of long-term adaptation to 
exercise. The hallmark of these alterations is a substantial 
enlargement of the heart due to both heart chamber 
dilatation and heart muscle mass hypertrophy. Although 
athlete’s heart has long been considered as a benign 
condition, there are data suggesting an association with 
sudden cardiac death (SCD) which can occur in athletes 
during exercise or even during daily activities.1 Indeed, 
hypertrophic cardiomyopathy (HCM), also characterized 
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by marked cardiac hypertrophy, is the most common 
cause of SCD in young athletes.2,3 The association 
between HCM and athlete’s heart has been a matter of 
extensive discussion and debate among clinicians since 
an eccentric biventricular hypertrophy is almost 
universally present in athletes with a left ventricular 
diastolic volume >58 mm. This conflict has not yet been 
resolved, but, we have nowadays evidence that the ECG, 
although commonly altered by athletic cardiac 
remodeling, can assist in selecting athletes who are at 
substantial risk for an episode of SCD.  
 
The Electrocardiogram in the Athlete 
The ECG is a simple and reproducible method to 
assess the risk of SCD and has been proposed as a useful 
tool for screening young persons who are willing to 
participate in high endurance training. ECG findings in 
athletes are divided in two categories: common or training 
related and uncommon or training unrelated changes 
(Table).4 The majority of these ECG findings are of no 
clinical significance, e.g. sinus bradycardia or an early 
repolarization ST-pattern. Only a minority of young 
athletes demonstrate abnormalities which require further 
diagnostic work-up, such as negative T waves or bundle 
branch blocks. Athletes with the ECG abnormalities listed 
in the Table should be more thoroughly assessed to 
exclude any severe underlying heart disease. 
 
Table 1. Classification of ECG Abnormalities in Athletes.4 
 
Common ECG 
abnormalities  
(training related) 
Uncommon ECG changes 
(training unrelated) 
Sinus bradycardia 
First degree AV block 
Incomplete RBBB 
Early repolarization 
Increased QRS voltage 
Complete LBBB, RBBB 
T wave inversion & ST depression 
Long QT 
Left atrial enlargement 
Left axis deviation/LAHB 
Right axis deviation/LPHB 
Pathological Q-wave 
Brugada-like ECG 
 
AV = atrio-ventricular; ECG = electrocardiogram; LAHB = left 
anterior hemiblock; LBBB = left bundle branch block; LPHB = left 
posterior hemiblock; RBBB = right bundle branch block 
 
Sinus bradycardia- Atrioventricular block 
Sinus bradycardia is extremely common in athletes. 
However, in case of persistent severe bradycardia along 
with pauses >3 s, further testing is needed. Increased 
parasympathetic tone is also associated with first degree 
atrioventricular (AV) block. Athletes with no symptoms 
(syncope, presyncope) or structural heart disease can 
participate in all sports. Nevertheless, symptomatic first 
degree AV block requires further investigation (exercise 
stress test, echocardiogram).5 On the other hand, the 
presence of Mobitz II AV block, 3o AV block, persistent 
sinus bradycardia or pauses >3 s are indications for a 
permanent pacemaker.6 Mobitz I (Wenckebach) 2o AV 
block is a frequent benign finding in well trained athletes, 
esp. at sleep or at rest. Thus, in asymptomatic athletes 
with Mobitz I block further testing is not recommended.5  
 
Right (RBBB) and Left Bundle Branch Block (LBBB) 
Intraventricular conduction abnormalities, i.e. in the 
form of complete bundle branch block are not common in 
athletes. Accordingly, whenever these abnormalities are 
present, exercise stress testing, Holter monitoring, and 
imaging studies are recommended in order to exclude 
ischemic heart disease, myocarditis, hypertensive heart 
disease, restrictive cardiomyopathy (e.g. sarcoidosis) and 
congenital heart disease. 
Athletes with no family history, negative physical 
examination and RBBB or LBBB, can participate in high 
endurance sports activities,7 only under the condition that 
they do not develop any AV conduction abnormalities 
during an exercise stress test.8  
 
Brugada syndrome 
Brugada type 1 ECG is characterized by a ‘coved’ ST-
segment elevation ≥2 mm (0.2 mV) followed by a 
negative T wave. Type 2 & 3 Brugada ECG shows a 
‘saddleback’ morphology.4 Brugada type 1 is not 
associated with SCD during exercise, but increased vagal 
tone at rest can trigger a malignant arrhythmic event. 
Nevertheless, athletes with Brugada type 1 ECG are not 
permitted to participate in competitive sports.8  
 
Increased QRS voltage- T wave inversion 
Highly trained athletes exhibit some degree of cardiac 
hypertrophy. On the other hand, HCM is an autosomal 
dominant genetic disease characterized by both 
myocardial hypertrophy and disarray. Increased QRS 
voltage without the presence of at least one other 
abnormality, such as ST segment depression, T wave 
inversion, or left axis deviation, is very rare in HCM. 
T-wave inversion >2 mm in the inferior and lateral 
leads needs to be further investigated to rule out ischemic 
heart disease, aortic valve disease and cardiomyopathy. 
On the other hand, inverted T waves in leads V1-V3 may 
be a normal finding in athletes <16 years old.9 Post-
pubertal athletes with persistent negative T wave in V1-V6 
require thorough investigation to exclude arrhythmogenic 
right ventricular cardiomyopathy (ARVC), including 
echocardiography, Holter monitoring, magnetic 
resonance imaging (MRI) and possibly genetic screening. 
 
Ventricular Premature Beats (VPBs) 
Young athletes with VPBs and no structural disease 
can participate in all competitive sports. If the number of 
VPBs increases during exercise and patient becomes 
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symptomatic, the athlete can participate in sports with the 
lowest total cardiovascular demand, i.e. <40% max O2 
(billiards, bowling, cricket, golf).10,11  
 
Wolff-Parkinson-White (WPW) Syndrome 
WPW syndrome is present in 0.3% of athletes.12 The 
ECG demonstrates short PR (<120 ms), wide QRS with 
delta wave and secondary ST-T changes. 
Atrioventricular reentry tachycardia (AVRT), either 
orthodromic (narrow QRS) or antidromic (wide QRS), is 
the most common tachycardia (95%) in WPW. Atrial 
fibrillation can be a life-threatening arrhythmia in these 
patients, as a short refractory period (<220 ms) of the 
accessory pathway can lead to a very rapid ventricular 
rate and degeneration into ventricular fibrillation. In 
symptomatic young athletes (palpitations, syncope) with 
WPW, an electrophysiology study is recommended.5 If an 
AVRT can be provoked during the study, ablation of the 
accessory pathway should be performed. On the other 
hand, even if the athlete with WPW is completely 
asymptomatic, an electrophysiology study is still required 
to give permission for participation in competitive sports. 
 
Long QT Syndrome (LQTS) 
QT prolongation may be transient in athletes due to 
acute electrolyte changes or abuse of specific substances 
and normalizes after de-conditioning. If QT prolongation 
persists, echocardiogram, Holter monitoring and exercise 
testing are recommended. Per the ESC guidelines, 
athletes with LQTS should be disqualified from sports.8  
 
Conclusion 
Cardiovascular remodelling in highly trained athletes 
is frequently associated with minor ECG abnormalities. 
ECG monitoring and classifying ECG findings into 
physiological or “common” or “training related” and 
pathological or “uncommon” or “training unrelated” 
changes, facilitates pre-participation screening. In the 
presence of ECG abnormalities not related to training, it 
is important to exclude any underlying heart disease 
associated with SCD (HCM, chanelopathies, etc) using 
more tests (e.g. MRI or eletrophysiology studies). 
Nevertheless, false –positive results that pose serious 
limitation to pre-participation screening also exist. 
Peliccia et al, in a study of 1005 young athletes, have 
demonstrated that the majority (60%) had no significant 
ECG changes.13 The rest (40%) had ECG changes not 
related to cardiomyopathy. In fact, young athletes in 
cycling or rowing had most typical changess as a result of 
adaptation of the heart after high endurance training with 
no echo or MRI evidence of cardiomyopathy.  
Thus, a new debate has been recently going on about 
whether an ECG should be part of the screening of 
apparently healthy young sporters. In Italy this screening 
is compulsory by law and the ESC supports this policy 
and has recently issued recommendations for the 
interpretation of the ECG in the athlete.14 However, 
others15 find the cost too high for its yield and an ECG is 
not included in the screening protocol of the AHA.16,17  
 
REFERENCES 
1.  Thompson PD, Franklin BA, Balady GJ, et al. Exercise and acute 
cardiovascular events placing the risks into perspective: a 
scientific statement from the AHA Council on Nutrition, Physical 
Activity, and Metabolism and the Council on Clinical Cardiology. 
Circulation 2007; 115: 2358-2368. 
2.  Corrado D, Basso C, Thiene G. Essay: Sudden death in young 
athletes. Lancet 2005; 366(Suppl 1): S47-S48. 
3.  Maron, BJ. Sudden death in young athletes. N Engl J Med 2003; 
349: 1064-1075. 
4.  Corrado D, Pelliccia A, Heidbuchel H, et al. Recommendations for 
interpretation of 12-lead electrocardiogram in the athlete. Eur 
Heart J 2010;31:243-259.   
5.  Zipes DP, Ackerman MJ, Estes NA 3rd, et al. Arrhythmias. J Am 
Coll Cardiol 2005; 45:1354.  
6.  Venerando A, Rulli V. Frequency morphology and meaning of the 
electro-cardiographic anomalies found in Olympic marathon 
runners and walker. J Sports Med Phys Fitness 1964;4:135-141. 
7.  Langdeau JB, Blier L, Turcotte H, O'Hara G, Boulet LP. ECG 
findings in athletes: the prevalence of left ventricular hypertrophy 
and conduction defects. Can J Cardiol 2001;17:655-659. 
8.  Pelliccia A, Fagard R, Bjørnstad HH, et al. Recommendations for 
competitive sports participation in athletes with cardiovascular 
disease: a consensus document from the Study Group of Sports 
Cardiology of Cardiac Rehabilitation & Exercise Physiology and 
the Working Group of Myocardial & Pericardial diseases of the 
ESC. Eur Heart J 2005: 26:1422-1445. 
9.  Corrado D, Pelliccia A, Bjørnstad HH, et al. Cardiovascular pre-
participation screening of young competitive athletes for 
prevention of sudden death: proposal for a common European 
protocol. Eur Heart J 2005;26:516-524. 
10. Mitchell JH, Haskell W, Snell P, Van Camp SP. Classification of 
sports. J Am Coll Cardiol 2005 ; 45:1364-1367. 
11. Zehender M, Meinertz T, Keul J, Just H. ECG variants and cardiac 
arrhythmias in athletes: clinical relevance and prognostic 
importance. Am Heart J 1990; 119:1378-1391. 
12. Hiss RG, Lamb LE. Electrocardiographic findings in 122 043 
individuals. Circulation 1962;25:947-961. 
13. Pelliccia A; Maron BJ, Culasso F, et al. Clinical significance of 
abnormal ECG patterns in trained athletes. Circulation 2000, 
102:278-284.  
14. Corrado D, Pellicia A, Heidbuchel H, et al. Recommendations for 
interpretation of 12-lead electrocardiogram in the athlete. Eur 
Heart J 2010;31:243–259. 
15. Chaitman BR. An ECG should not be included in routine 
preparticipation screening of young athletes. Circulation 
2007;116:2610-2614. 
16. Maron BJ, Thompson PD, Ackerman MJ, et al. Recommendations 
and consideration related to preparticipation screening for 
cardiovascular abnormalities in competitive athletes: 2007 update: 
a scientific statement for the AHA Council on Nutrition, Physical 
Activity and Metabolism: endorsed by the ACC Foundation. 
Circulation 2007;115:1643-1655. 
17. Myerburg RJ, Vetter VL. ECGs should be included in 
preparticipation screening of athletes. Circulation 2007;116:2616-
2626. 
